Clinical Trials Logo
  1. Home
  2. Therapeutic Equivalency
  3. NCT03930264

Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®) — AZA  

Therapeutic Equivalency Clinical Trial

Official title:
A Single Centre, Two Period Crossover Study to Assess the Bioequivalence of an Oral Azathioprine Suspension 10 mg/mL (Jayempi™) Versus Oral Azathioprine Tablet 50mg (Imurek®) in at Least 30 Healthy Adult Subjects Under Fasting Conditions

Clinical Trial Summary

A single center, single dose, open-label, randomized, two period crossover study to assess the bioequivalence of an oral azathioprine suspension 10 mg/mL (Jayempi™) versus oral azathioprine tablet 50mg (Imurek®, Aspen Pharma Trading Limited, Dublin, Ireland.) in at least 30 healthy adult subjects under fasting conditions.

Clinical Trial Description

This will be a single-dose, open-label, randomised, two-period crossover study with orally administered 1 x 5mL (50 mg) of Jayempi™ Oral Suspension 10mg/mL versus oral azathioprine tablet 50mg (Imurek®, Aspen Pharma Trading Limited, Dublin, Ireland) on two separate occasions conducted under fasting conditions in healthy male and female subjects at a single study centre. The study will comprise: - Thiopurine methyltransferase (TPMT) testing; - Screening period of maximum 28 days - Two treatment periods (each of which will include a PK profile period of 12 hours) separated by a wash-out period of at least 3 calendar days (minimum number of days based on half-life of the analyte) and maximum of 14 calendar days between consecutive administrations of the IMP - A post-study visit 7-10 days after the last dose of the last treatment period of the study. Subjects will be randomly assigned to treatment sequence, prior to the first administration of IMP. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03930264
Study type Interventional
Source Nova Laboratories Limited
Contact
Status Completed
Phase Phase 1
Start date April 11, 2019
Completion date May 31, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT04467346 - Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules Phase 1
Completed NCT00807118 - Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect Phase 1
Withdrawn NCT01405170 - A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions Phase 1
Completed NCT04885660 - Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects Phase 1
Completed NCT05786339 - Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects Phase 1
Completed NCT00709189 - Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women. Phase 1
Completed NCT00658541 - Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets Phase 1
Completed NCT00685165 - Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets Phase 1
Completed NCT00997789 - Bioequivalence of Rebamipide in Korean N/A
Completed NCT00684762 - Fasted Bioavailability Study of Cilostazol Tablets, 100 mg Phase 1
Recruiting NCT04814589 - Bioequivalence of Ezetimibe Tablets in Healthy Subjects Phase 1
Completed NCT03631316 - Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir N/A
Recruiting NCT04438720 - Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects Phase 1
Completed NCT01359163 - A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects Phase 1
Completed NCT00650221 - Fasting Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects Phase 1
Completed NCT00648544 - Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects Phase 1
Completed NCT05225974 - A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects Phase 1
Withdrawn NCT01405157 - A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions Phase 1
Withdrawn NCT01405131 - A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Phase 1
Completed NCT05282940 - Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product Phase 1